Purpose: To determine risk factors for the development of gallstones and the prevalence of related cholecystectomy in children following hematopoietic cell transplantation (HCT).
decreased physical activity, Crohn disease, and hemolysis. 3 In childhood cancer, gallstones have been associated with ileal conduit, parenteral nutrition, abdominal surgery, and abdominal radiation therapy. 4 In 1 study of childhood HCT patients, gallstones were more frequent in children treated for bone marrow failure than malignancy. 2 In HCT patients, virtually all patients who receive myeloablative pretransplant conditioning therapy develop biliary sludge (microliths), which may promote the development of gallstones. 5 In addition, calcineurin inhibitors (such as cyclosporine and tacrolimus) used for immunosuppression have been associated with an increased incidence of gallstones after kidney and heart transplantation. 6, 7 The purpose of this study was to determine the incidence and risk factors for the development of gallstones in over 1300 childhood HCT patients and to describe the prevalence of a history of cholecystectomy among longterm survivors.
MATERIALS AND METHODS

Patient Selection
Between 1969 and January 1, 2011, a total of 1365 consecutive children below 18 years of age received transplant conditioning therapy and survived at least 1 year after HCT at the Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA. Excluded from the analysis were 22 patients who did not consent to follow-up or who were incarcerated. The remaining 1343 patients or their responsible guardians consented to follow-up under Protocol 999.2 and the data were reviewed under Protocol 1782 approved by the FHCRC Institutional Review Board. Eighteen patients who had developed gallstones or undergone cholecystectomy before HCT were excluded from the analysis and the remaining 1325 were analyzed.
Transplant Preparative Regimen, Source of Stem Cells, Supportive Care, and Follow-up Transplant preparative regimens included either chemotherapy or chemoradiotherapy as previously described. [8] [9] [10] [11] [12] [13] Most chemotherapy-only regimens utilized cyclophosphamide (50 mg/kg/d) for 4 days alone or combined with busulfan (4 mg/kg/d) for 4 days. 9, 11 Most total body irradiation (TBI) regimens included cyclophosphamide (60 mg/kg/d) for 2 days. From 1969 to 2000, TBI was delivered from dual-opposing cobalt-60 sources at a dose rate in air of 5 to 8 cGy/min as either 9.2 to 10.0 Gy single-exposure TBI or fractionated TBI with exposures of 2.0 to 2.75 Gy for 6 to 7 consecutive days or hyperfractionated exposures of 1.2 Gy 2 to 3 times daily for 4 consecutive days (total dose 12.0 to 15.75 Gy). 8, 9, 12, 13 TBI in reduced intensity regimens was given as 2.0 Gy 1 to 2 times daily for 1 to 2 days. From 2001 onward, TBI was delivered by linear accelerator.
Allogeneic transplant recipients received either bone marrow, peripheral blood, or umbilical cord blood stem cells harvested from related or unrelated donors. All allogeneic transplant recipients received prophylaxis for acute graft-versus-host disease (GVHD) depending on the type of donor and protocol in use at time of HCT and generally included methotrexate and a calcineurin inhibitor (cyclosporine or tacrolimus), but less often included corticosteroids, antithymocyte globulin, mycophenolate mofetil, or monoclonal antibodies as additional prophylactic agents. [14] [15] [16] Acute and chronic GVHD were diagnosed, graded, and treated as previously described. [17] [18] [19] [20] All patients received antibacterial prophylaxis, and some also received antifungal and antiviral prophylaxis as well as use of laminar airflow rooms, growth factors, and intravenous immunoglobulin according to the standard of practice at the time of transplant. Most patients had indwelling central venous catheters and received nutritional support with hyperalimentation. Ursodeoxycholic acid (ursodiol) prophylaxis for hepatic complications was given from 2003 onward at 12 mg/kg/d starting approximately 2 weeks before conditioning and continuing until day + 60, + 90, and + 180 for autologous transplants, myeloablative, and nonmyeloablative regimens of allogeneic transplants, respectively.
All surviving patients had an evaluation for engraftment and chronic GVHD at 80 to 100 days after transplant. Patients returned to FHCRC for long-term follow-up at 1 year and electively thereafter. Follow-up after 1 year consisted of annual contact with referring physicians from 1969 to 1990, and by questionnaires mailed annually to patients and their primary medical provider from 1991 to the present. Eighty percent of patients had been contacted within 3 years of the study date.
Study Data
Data were obtained from the FHCRC clinical information database, transplant flow sheets, and long-term follow-up records. Study data were collected through March 1, 2013. Gallstones were defined as incidental or symptomatic based on whether or not the patient had signs and symptoms of biliary disease at the time diagnostic scans were performed.
Body mass index (BMI, kg/m 2 ) was calculated based on patient height and weight at last follow-up (except for those with gallstones whose BMI at time of gallstone diagnosis was used). Obesity was defined as a BMIZ95th percentile based on age and sex in patients below 18 years old and a BMIZ30 in patients 18 years and above. 21, 22 Abdominal surgery was defined as any surgery involving the peritoneal cavity, excluding hernia surgery. Abdominal irradiation was defined as local irradiation given before or shortly after HCT to the abdomen, pelvis, renal, adrenal, retroperitoneal, or lower spine. Estrogen therapy was defined as oral contraceptive use or estrogen replacement therapy. Pregnancy included both miscarriages and childbirth.
Study Endpoints, Variables, and Statistical Methods
For the purpose of analysis, transplant diagnoses were categorized into 6 groups: acute lymphoblastic leukemia (ALL); acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), and juvenile myelomonocytic leukemia (JMML), and myeloproliferative disorders (AML/MDS/JMML/MPD); other hematologic malignancies; other malignancies; aplastic anemia; and other nonmalignant disorders. Other hematologic malignancies included chronic myelogenous leukemia (CML), Hodgkin disease, and non-Hodgkin lymphoma. Other malignancies included neuroblastoma (n = 105), brain tumors (n = 14), Ewing sarcoma (n = 12), Wilms tumor (n = 6), germ cell (n = 5), and retinoblastoma (n = 1). Other nonmalignant disorders included histiocytic diseases (10 hemophagocytic lymphohistiocytosis and 2 Langerhans cell histiocytosis), primary immunodeficiency (n = 51), red cell dysplasia (n = 22), metabolic disorders (n = 7), and other miscellaneous diseases (n = 14).
Other baseline variables selected for analysis included: sex, race/ethnicity (non-Hispanic white vs. other race/ethnicity), age at transplantation (below 9 vs. 9 to below 18 y), year of transplant (1969 to 1989 vs. 1990 to 2011), TBI (none, low dose, high dose), donor type (sibling vs. other related vs. unrelated vs. autologous), HLA matching between donor and recipient (matched or mismatched defined as Z1 antigen mismatches at HLA-A, HLA-B, or HLA-DRB1), acute GVHD prophylaxis (MTX based, cyclosporine based, tacrolimus/other based, none), acute GVHD grade (0 vs. 1 to 2 vs. 3 to 4), abdominal surgery (yes/no), local abdominal irradiation (yes/no), and ursodiol prophylaxis (yes/no). In addition, the following time-dependent variables were included: clinical extensive chronic GVHD, calcineurin inhibitors for prophylaxis or treatment, calcineurin inhibitors for chronic GVHD therapy, second HCT, obesity, diabetes, estrogen therapy, and pregnancy.
Statistical analysis was performed for symptomatic gallstones and repeated for both symptomatic and incidental gallstones. Cumulative incidence curves for the development of gallstones were estimated by standard methods, treating death without gallstones and cholecystectomy performed for conditions unrelated to gallstones as competing risks. Cox regression was used for hazard ratio (HR) analysis with adjustment for covariates. Posttransplant events were entered as time-dependent covariates at the time the events occurred. Overall tests of significance reflect likelihood ratio tests; comparisons of individual levels to the reference level reflect Wald tests. All P-values are 2-sided.
The point prevalence of cholecystectomy among surviving patients was calculated using the formula (patients with a history of cholecystectomy/total surviving patients at risk) as of March 1, 2013.
RESULTS
Patient Population
Patient and transplant characteristics are presented in Table 1 . Median follow-up was 20.4 (range, 1.0 to 40.1) years. Ninety-one patients developed gallstones, a median of 3.5 (range, 0.1 to 30.9) years after first HCT at 16.3 (range, 0.8 to 44.2) years of age.
Among the 91 patients who developed gallstones, 79 had received allogeneic transplants. Among these 79 patients, gallstones developed in 7 patients before day 100 (3 before onset of acute GVHD, 2 after acute GVHD, and 2 who did not develop acute GVHD). Of the remaining 72 patients, 35 did not develop chronic GVHD, 2 developed gallstones before chronic GVHD, and 35 developed gallstones after chronic GVHD. Among the 35 patients who developed gallstones after chronic GVHD, 23 had been treated with calcineurin inhibitors (14 cyclosporine, 5 tacrolimus, and 4 both cyclosporine and tacrolimus), 11 received prednisone alone (n = 6) or combined with azathioprine (n = 3), cyclophosphamide and azathioprine (n = 1), or rapamycin (n = 1), and 1 patient was untreated. Eight patients developed gallstones a median of 8.0 years (range, 0.2 to 20.8) after second transplant.
Gallstone Diagnosis, Treatment, and Pathology
Initial Diagnosis
At initial diagnosis of gallstones, 9 (10%) had received ursodiol prophylaxis and 13 (14%) had received ceftriaxone during the first 100 days after transplant. Among 27 patients who developed gallstones <1 year after transplant, 10 were receiving parental nutrition at the time of diagnosis of gallstones and 17 had completed TPN. Among all 91 patients, 30 had evidence of biliary sludge on diagnostic scans performed on or before the diagnosis of gallstones, 9 had diabetes, 6 were receiving treatment for dyslipidemia (2 statin and fibrate, 2 statin, 1 niacin, 1 ezetimibe and fibrate), 1 had liver cirrhosis, and none of the patients had reported Crohn disease. Among 40 female patients, 15 were on estrogen therapy and 6 had stopped estrogen therapy a median of 5 (range, 1 to 12) years earlier. Seven patients had prior pregnancies (5 childbirths and 2 miscarriages). Among the 91 patients who developed gallstones, 61 (67%) patients were symptomatic and 30 (23%) had incidental stones at initial diagnosis.
Symptomatic Gallstones
Symptomatic stones were found in 61 patients (49 with hematologic malignancies and 12 nonmalignant disorders) a median of 6.3 (range, 0.1 to 30.9) years after HCT. After initial diagnosis, 45 (74%) patients underwent cholecystectomy (32 within 60 d of diagnosis, 13 a median of 3.8 [range, 0.2 to 25.7] y later), 5 died with persistent stones, 5 were alive with persistent stones, and 6 had resolution of their stones. Resolution of gallstones occurred spontaneously (n = 3) and following treatment with ursodiol (n = 3). One 42-year-old patient died of congestive heart failure and myocardial infarction within 2 days following cholecystectomy.
Incidental Gallstones
Incidental stones were found in 30 patients (17 with hematologic malignancies, 6 nonhematologic malignancies, and 7 nonmalignant disorders) a median of 2.4 (range, 0.1 to 29.4) years after HCT. Incidental stones were discovered on diagnostic scans performed in 11 patients for cancer staging, 8 liver abnormalities (4 hepatitis C virus workup, 2 elevated liver function tests, 1 liver GVHD, and 1 hepatoma), 5 kidney abnormalities (3 kidney stones, 1 renal cyst, 1 fungal disease), and 6 miscellaneous reasons. After initial diagnosis, 10 patients became symptomatic and underwent cholecystectomy a median of 2.4 (range, 0.4 to 11.3) years later and 1 had an elective cholecystectomy. Nineteen patients remained asymptomatic. Of these, 10 had ongoing incidental stones a median of 6.7 (range, 0.8 to 19.9) years later and 9 patients had died (3 disease relapse, 3 secondary malignancies, and 3 other causes).
Pathology
Among the 56 patients who underwent cholecystectomy, pathology reports were available for 20 patients. Sixteen cases had chronic cholecystitis and 4 had acute and chronic cholecystitis. Gallstones were reported in wThree patients developed gallstones before acute GVHD and 7 were not evaluable for acute GVHD.
zExcluded were 7 patients who developed gallstones before day 100, autologous-only HCT recipients, and 10 patients who were unevaluable.
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; GVHD, graft-versushost disease; HCT, hematopoietic cell transplantation; HLA, human leukocyte antigen; JMML, juvenile myelomonocytic leukemia; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; TBI, total body irradiation. 14 cases. Three cases had 1 to 2 gallstones, 7 had multiple gallstones, and 4 had an unspecified number. Stone composition by color was cholesterol (yellow/green, n = 6), pigmented (black/brown, n = 4), mixed type (n = 2), and unspecified (n = 2). One case with a cholesterol gallstone also had gallbladder cholesterolosis. Two stones were impacted in the cystic duct.
Risk Factors for Gallstones
In univariate analysis, we found no significant difference between patients with and without gallstones with respect to sex (P = 0.67), race (P = 0.84), ursodiol prophylaxis (P = 0.74), and obesity (P = 0.58). The results of univariate analysis are presented in Table 2 . All of the variables significant (P < 0.05) in univariate analysis were entered into the multivariate model.
The results of multivariate analysis are shown in Table 3 . Gallstones were significantly associated with autologous transplant (HR = 2.73, P = 0.02), unrelated donor (HR = 1.95, P = 0.05), grade 3 to 4 acute GVHD (HR = 2.20, P = 0.03), clinical extensive chronic GVHD (HR = 1.98, P = 0.05), second transplant (HR = 2.28, P = 0.03), diabetes (HR = 2.16, P = 0.05), and estrogen therapy (HR = 1.77, P = 0.03).
Because of concern that inclusion of incidental gallstones may have affected the results, multivariate analysis was repeated including only symptomatic gallstones (n = 71). Excluding incidental stones, symptomatic gallstones remained significantly associated in multivariate analysis with unrelated donor (HR = 2.22, P =0.02), clinical extensive chronic GVHD (HR = 2.49, P = 0.01), and second transplant (HR = 2.49, P = 0.03). Mismatched donor transplants became more significant (HR = 1.89, P = 0.04), whereas autologous transplant (P = 0.15), grade 3 to 4 acute GVHD (P = 0.13), diabetes (P = 0.11), and estrogen therapy (P = 0.10) became less significant. Pregnancy, which was previously not included in the multivariate model, was significantly associated with symptomatic gallstones (HR = 3.75, P = 0.006).
As shown in Figure 1 , the cumulative incidence of gallstones (symptomatic and incidental) was 11% at 40 years after HCT. Figure 2 shows the cumulative incidence of gallstones by donor type.
Prevalence of Cholecystectomy
Among the 91 gallstone patients, 28 had died. Among the remaining 63 patients, 44 had undergone cholecystectomy. Prevalence data are shown in Table 4 . The overall prevalence of cholecystectomy was 5.2% (44/853) among current survivors. Compared with the general population, 23 the prevalence of cholecystectomy among male survivors was roughly 2-to 4-fold higher at every age category below 50 years of age, whereas female survivors had a decreased prevalence of cholecystectomy at every age category except 30-to 39-year-olds for which the prevalence was nearly double.
DISCUSSION
This is the first study to report the frequency of the development of incidental and symptomatic gallstones in a large population following childhood HCT. Our study reports a much higher incidence of gallstones than previous studies of childhood cancer and HCT patients. In our study, among 1325 patients with up to 40 years of followup, 91 (6.9%) patients developed gallstones, which is 2-fold higher than the 3.5% (20/575) previously reported among childhood HCT patients. 2 Furthermore, the cumulative wIncluded as a time-dependent variable. ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CI, confidence interval; GVHD, graft-versus-host disease; HLA, human leukocyte antigen; HR, hazard ratio; JMML, juvenile myelomonocytic leukemia; MDS, myelodysplastic syndrome.
incidence of gallstones seems to rise with increasing length of follow-up reaching 11% at 40 years after transplant compared with 1.03% in childhood cancer patients at 18 years after diagnosis. 4 Our cumulative incidence of gallstones is comparable with a 9.7% history of gallstones reported in 1 study of long-term childhood and adult HCT survivors treated for CML. 24 The major finding of this study was an association of gallstone formation with multiple risk factors including autologous transplant, unrelated donor, grade 3 to 4 acute GVHD, clinical extensive chronic GVHD, second transplant, diabetes, and estrogen therapy.
Biliary sludge is found by ultrasound in approximately 70% 25 and at autopsy in 100% of HCT patients following myeloablative conditioning. 26 In 1 study of HCT patients, biliary sludge consisted primarily of unmeasurable residue, calcium bilirubinate, and a calcium-binding protein. 26 Biliary sludge may serve as nucleating material for the development of gallstones during the immediate period following transplantation. However, over time, most of the sludge is emptied from the gallbladder as patients resume eating. As the risk from biliary sludge-induced gallstones diminishes, our findings suggest that other risk factors or combination of risk factors contribute to gallstone formation.
Autologous transplant was associated with a 2-fold increased risk of gallstones. It is unlikely that autologous transplantation itself should be associated with gallstone formation, but may be a surrogate measure of other risk factors. In our study population, a majority of autologous patients were transplanted for neuroblastoma and other solid tumors that are frequently treated with abdominal surgery and/or abdominal irradiation, which were associated with a nonsignificant increased risk of gallstones in univariate analysis. In addition, nonhematologic US population data from Everhart et al. 23 malignancy patients undergo frequent restaging scans and are thus more likely to have incidental gallstones identified. Among allogeneic transplants, unrelated donors had a significant increased risk of gallstones. The increased risk is likely attributable to a higher risk of developing acute and chronic GVHD compared with related donors. Both grade 3 to 4 acute GVHD and clinical extensive chronic GVHD were associated with a 2-fold increase in gallstone formation. Acute GVHD of the gastrointestinal tract is associated with bile acid malabsorption. 27 Bile acid malabsorption may lead to an increase in biliary cholesterol supersaturation and cholesterol crystal formation, which in turn may lead to cholesterol gallstone formation. 28 In addition, the risk associated with acute GVHD may be attributable to other factors that promote gallstone formation, including increased use of parental nutrition, narcotics, and immunosuppressive agents, as well as, weight loss and decreased physical activity. Whereas acute and chronic GVHD were associated with gallstone formation, we found that treatment of GVHD with calcineurin inhibitors was not associated with gallstones in multivariate analysis. Our findings suggest that calcineurin inhibitors are not a significant risk factor for gallstone formation in HCT patients, unlike kidney and heart transplant patients in whom long-term cyclosporine-based and tacrolimus-based immunosuppression has been associated with an increased risk of gallstones. 6, 7 After the initial transplant period, development of gallstones was associated with a second transplant, developing diabetes, and estrogen therapy. Second transplant was associated with a 2-fold increased risk of gallstones likely reflecting all of the risk factors associated with a first transplant. Diabetes is a well-known risk factor for gallstones, 3 and childhood HCT patients have an increased risk of developing diabetes. 29 Estrogen therapy in females was associated with an increased risk of gallstones as has been described in the general population. 3 Gonadal failure is common in female childhood HCT survivors, usually related to busulfan or TBI exposure, and generally requires long-term estrogen replacement therapy. 1 In addition to the aforementioned risk factors, individual patients had various conditions that may have contributed to gallstone formation, including TPN use, ceftriaxone exposure, and liver cirrhosis. Childhood HCT patients have an increased risk of developing dyslipidemia as part of the metabolic syndrome, 30 which may also contribute to gallstone formation. The majority of gallstones available for analysis were cholesterol stones suggesting that dyslipidemia may contribute to gallstone formation in our patients. Interestingly, some patients developed gallstones despite being on statin therapy.
We compared the prevalence of a history of cholecystectomy in our HCT patients to that in the general population. 23 As expected, the prevalence of cholecystectomy for men in our study was roughly 2 to 4 times higher reflecting the relatively low rate of gallstone development among men in the general population. Similarly, the prevalence of cholecystectomy for women 30 to 39 years old in our study was nearly double, although the prevalence among other female age groups was lower than the general population possibly reflecting the higher rate of gallstone development in women in the general population.
The medical management of gallstones after HCT in children is poorly defined. In the general population, the natural history of gallstones results in cholecystectomy in 22% of patients. 31 In 1 study of 235 pediatric HCT patients, 15% of patients with gallstones underwent cholecystectomy due to acute cholecystitis, whereas the majority of asymptomatic patients were managed nonoperatively. 2 In our study, 62% of patients with gallstones underwent cholecystectomy (74% with symptomatic gallstones and 37% with incidental gallstones). The reason for the 4-fold increased rate of cholecystectomy is likely due to longer follow-up and the development of chronic cholecystitis or biliary obstruction. Our findings suggest that incidental gallstones may be followed nonoperatively, although a third of patients will become symptomatic. Most symptomatic patients required cholecystectomy; however, in a few cases, gallstones resolved without surgical intervention. Although cholecystectomy is generally considered a safe surgical procedure, 1 patient died of complications following cholecystectomy.
Our study had several limitations. This was a retrospective study and the identification of cases of gallstones was dependent on patients and/or their physicians in providing follow-up information. Our data are heavily biased toward reports of symptomatic gallstones with an underreporting of incidental gallstones, likely understating the true incidence of gallstones in our population as discussed above. Because of the potential that incidental gallstones may have affected our results, we performed the multivariate analysis with and without incidental gallstones. In general, the results for symptomatic gallstones were similar, although some variables were less significant presumably due to a smaller sample size and autologous transplantation in particular was less significant most likely due to its association with incidental gallstones as discussed above. We were also limited in our ability to assess certain potential risk factors including family history and genetics, rapid weight loss, diet, dyslipidemia, decreased physical activity, and hemolysis. We were also unable to assess the role of statins in preventing gallstones. Lastly, other factors such as the impact of TPN could not be assessed as most HCT patients receive TPN in the weeks following HCT, but the total duration of TPN therapy is not routinely collected.
CONCLUSIONS
Long-term survivors of childhood HCT are at risk for gallstones and gallstone complications in the years following transplant, especially those who had an autologous transplant, unrelated donor, grade 3 to 4 acute GVHD, clinical extensive chronic GVHD, second transplant, diabetes, and females treated with estrogen therapy.
